Clinical Trial

Stroke Prevention in Nigeria 2 Trial

Study acronym: SPRING-2
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary goal of this study is to complete a multicenter single-arm, type I hybrid trial to assess the effectiveness of hydroxyurea therapy for primary stroke prevention in high-risk children with sickle cell anemia (SCA) living in Nigeria in routine care settings.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-23; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2024-08-26
Trial Details
NCT Number NCT06526117
Lead Sponsor Vanderbilt University Medical Center
Collaborators: Aminu Kano Teaching Hospital, Murtala Muhammed Specialist Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Sickle Cell Disease, Stroke
Enrollment 220 participants
Start Date 2024-08-05
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-05